Cargando…

Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides

The therapeutic and research potentials of oligonucleotides (ONs) have been hampered in part by their inability to effectively escape endosomal compartments to reach their cytosolic and nuclear targets. Splice-switching ONs (SSOs) can be used with endosomolytic small molecule compounds to increase f...

Descripción completa

Detalles Bibliográficos
Autores principales: Bost, Jeremy P., Ojansivu, Miina, Munson, Michael J., Wesén, Emelie, Gallud, Audrey, Gupta, Dhanu, Gustafsson, Oskar, Saher, Osama, Rädler, Julia, Higgins, Stuart G., Lehto, Taavi, Holme, Margaret N., Dahlén, Anders, Engkvist, Ola, Strömstedt, Per-Erik, Andersson, Shalini, Edvard Smith, C. I., Stevens, Molly M., Esbjörner, Elin K., Collén, Anna, El Andaloussi, Samir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888659/
https://www.ncbi.nlm.nih.gov/pubmed/35233031
http://dx.doi.org/10.1038/s42003-022-03132-2
_version_ 1784661208037588992
author Bost, Jeremy P.
Ojansivu, Miina
Munson, Michael J.
Wesén, Emelie
Gallud, Audrey
Gupta, Dhanu
Gustafsson, Oskar
Saher, Osama
Rädler, Julia
Higgins, Stuart G.
Lehto, Taavi
Holme, Margaret N.
Dahlén, Anders
Engkvist, Ola
Strömstedt, Per-Erik
Andersson, Shalini
Edvard Smith, C. I.
Stevens, Molly M.
Esbjörner, Elin K.
Collén, Anna
El Andaloussi, Samir
author_facet Bost, Jeremy P.
Ojansivu, Miina
Munson, Michael J.
Wesén, Emelie
Gallud, Audrey
Gupta, Dhanu
Gustafsson, Oskar
Saher, Osama
Rädler, Julia
Higgins, Stuart G.
Lehto, Taavi
Holme, Margaret N.
Dahlén, Anders
Engkvist, Ola
Strömstedt, Per-Erik
Andersson, Shalini
Edvard Smith, C. I.
Stevens, Molly M.
Esbjörner, Elin K.
Collén, Anna
El Andaloussi, Samir
author_sort Bost, Jeremy P.
collection PubMed
description The therapeutic and research potentials of oligonucleotides (ONs) have been hampered in part by their inability to effectively escape endosomal compartments to reach their cytosolic and nuclear targets. Splice-switching ONs (SSOs) can be used with endosomolytic small molecule compounds to increase functional delivery. So far, development of these compounds has been hindered by a lack of high-resolution methods that can correlate SSO trafficking with SSO activity. Here we present in-depth characterization of two novel endosomolytic compounds by using a combination of microscopic and functional assays with high spatiotemporal resolution. This system allows the visualization of SSO trafficking, evaluation of endosomal membrane rupture, and quantitates SSO functional activity on a protein level in the presence of endosomolytic compounds. We confirm that the leakage of SSO into the cytosol occurs in parallel with the physical engorgement of LAMP1-positive late endosomes and lysosomes. We conclude that the new compounds interfere with SSO trafficking to the LAMP1-positive endosomal compartments while inducing endosomal membrane rupture and concurrent ON escape into the cytosol. The efficacy of these compounds advocates their use as novel, potent, and quick-acting transfection reagents for antisense ONs.
format Online
Article
Text
id pubmed-8888659
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-88886592022-03-17 Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides Bost, Jeremy P. Ojansivu, Miina Munson, Michael J. Wesén, Emelie Gallud, Audrey Gupta, Dhanu Gustafsson, Oskar Saher, Osama Rädler, Julia Higgins, Stuart G. Lehto, Taavi Holme, Margaret N. Dahlén, Anders Engkvist, Ola Strömstedt, Per-Erik Andersson, Shalini Edvard Smith, C. I. Stevens, Molly M. Esbjörner, Elin K. Collén, Anna El Andaloussi, Samir Commun Biol Article The therapeutic and research potentials of oligonucleotides (ONs) have been hampered in part by their inability to effectively escape endosomal compartments to reach their cytosolic and nuclear targets. Splice-switching ONs (SSOs) can be used with endosomolytic small molecule compounds to increase functional delivery. So far, development of these compounds has been hindered by a lack of high-resolution methods that can correlate SSO trafficking with SSO activity. Here we present in-depth characterization of two novel endosomolytic compounds by using a combination of microscopic and functional assays with high spatiotemporal resolution. This system allows the visualization of SSO trafficking, evaluation of endosomal membrane rupture, and quantitates SSO functional activity on a protein level in the presence of endosomolytic compounds. We confirm that the leakage of SSO into the cytosol occurs in parallel with the physical engorgement of LAMP1-positive late endosomes and lysosomes. We conclude that the new compounds interfere with SSO trafficking to the LAMP1-positive endosomal compartments while inducing endosomal membrane rupture and concurrent ON escape into the cytosol. The efficacy of these compounds advocates their use as novel, potent, and quick-acting transfection reagents for antisense ONs. Nature Publishing Group UK 2022-03-01 /pmc/articles/PMC8888659/ /pubmed/35233031 http://dx.doi.org/10.1038/s42003-022-03132-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Bost, Jeremy P.
Ojansivu, Miina
Munson, Michael J.
Wesén, Emelie
Gallud, Audrey
Gupta, Dhanu
Gustafsson, Oskar
Saher, Osama
Rädler, Julia
Higgins, Stuart G.
Lehto, Taavi
Holme, Margaret N.
Dahlén, Anders
Engkvist, Ola
Strömstedt, Per-Erik
Andersson, Shalini
Edvard Smith, C. I.
Stevens, Molly M.
Esbjörner, Elin K.
Collén, Anna
El Andaloussi, Samir
Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides
title Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides
title_full Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides
title_fullStr Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides
title_full_unstemmed Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides
title_short Novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides
title_sort novel endosomolytic compounds enable highly potent delivery of antisense oligonucleotides
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8888659/
https://www.ncbi.nlm.nih.gov/pubmed/35233031
http://dx.doi.org/10.1038/s42003-022-03132-2
work_keys_str_mv AT bostjeremyp novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT ojansivumiina novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT munsonmichaelj novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT wesenemelie novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT galludaudrey novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT guptadhanu novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT gustafssonoskar novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT saherosama novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT radlerjulia novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT higginsstuartg novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT lehtotaavi novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT holmemargaretn novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT dahlenanders novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT engkvistola novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT stromstedtpererik novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT anderssonshalini novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT edvardsmithci novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT stevensmollym novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT esbjornerelink novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT collenanna novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides
AT elandaloussisamir novelendosomolyticcompoundsenablehighlypotentdeliveryofantisenseoligonucleotides